HI
REGN icon

HBK Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

HBK Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,400
Closed -$2.4M – 424
2019
Q4 		$2.4M Buy
6,400
+4,000
+167% +$1.35M 0.02% 399
2019
Q3 		$666K Buy
+2,400
New +$710K 0.01% 523

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

HBK Investments's REGN Position: Q1 2020 in Review

HBK Investments sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 12,870 shares — an estimated $4.83M sold.

HBK Investments first reported a position in REGN in Q2 2013 and held it in 14 quarters. The position peaked at $20.9M in Q4 2013. 817 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • HBK Investments reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • HBK Investments sold 12,870 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $4.83M.
  • HBK Investments first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • HBK Investments's Regeneron Pharmaceuticals position peaked at $20.9M in Q4 2013.
  • 817 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on HBK Investments's 13F filing for Q1 2020, filed 15 May 2020.